Prevail Therapeutics Inc.
DelistedCIK 1714798fmd_0T1PA9RN6PFKAWWKW3HAT0V7ERManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2020, 10 periods
Latest annual · FY2019
Millions- Operating income
- (66)
- Net income
- (63)
- Free cash flow
- (58)
Latest quarter · Q3 FY2020
Millions- Operating income
- (19)
- Net income
- (19)
- Free cash flow
- (17)
Prevail Therapeutics Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2019 | FY2018 | Change | Source |
|---|---|---|---|---|
| Operating income | -$65.8 million | -$18.8 million | 10-K 2020-03-26 · proof | |
| Net income | -$63.2 million | -$19.1 million | 10-K 2020-03-26 · proof | |
| Cash from operating activities | -$55.8 million | -$14 million | 10-K 2020-03-26 · proof | |
| Free cash flow | -$57.9 million | -$14.6 million | 10-K 2020-03-26 · proof | |
| Total assets | $187.1 million | $72.9 million | +156.7% | 10-K 2020-03-26 · proof |
| Total liabilities | $21.8 million | $11.6 million | +87.8% | 10-K 2020-03-26 · proof |
| Cash and cash equivalents | $168.1 million | $63 million | +166.7% | 10-K 2020-03-26 · proof |
- What was Prevail Therapeutics Inc.'s operating income in fiscal 2019?
- Prevail Therapeutics Inc. reported operating income of -$65.8 million for fiscal 2019 (the year ended Dec 31, 2019), against -$18.8 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2020. SEC
- What was Prevail Therapeutics Inc.'s net income in fiscal 2019?
- Prevail Therapeutics Inc. reported net income of -$63.2 million for fiscal 2019 (the year ended Dec 31, 2019), against -$19.1 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2020. SEC
- What was Prevail Therapeutics Inc.'s cash from operating activities in fiscal 2019?
- Prevail Therapeutics Inc. reported cash from operating activities of -$55.8 million for fiscal 2019 (the year ended Dec 31, 2019), against -$14 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2020. SEC
- What was Prevail Therapeutics Inc.'s free cash flow in fiscal 2019?
- Prevail Therapeutics Inc. reported free cash flow of -$57.9 million for fiscal 2019 (the year ended Dec 31, 2019), against -$14.6 million the year before. Source: the 10-K filed with the SEC on Mar 26, 2020. SEC
- What are Prevail Therapeutics Inc.'s total assets?
- As of Dec 31, 2019, Prevail Therapeutics Inc. reported total assets of $187.1 million, against $72.9 million a year earlier (+156.7%). Source: the 10-K filed with the SEC on Mar 26, 2020. SEC
- What are Prevail Therapeutics Inc.'s total liabilities?
- As of Dec 31, 2019, Prevail Therapeutics Inc. reported total liabilities of $21.8 million, against $11.6 million a year earlier (+87.8%). Source: the 10-K filed with the SEC on Mar 26, 2020. SEC
- What are Prevail Therapeutics Inc.'s cash and cash equivalents?
- As of Dec 31, 2019, Prevail Therapeutics Inc. reported cash and cash equivalents of $168.1 million, against $63 million a year earlier (+166.7%). Source: the 10-K filed with the SEC on Mar 26, 2020. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1714798&period_type=annual&limit=5"Information only, not investment advice.